SteadyMed Ltd. (NASDAQ: STDY) is a specialty pharmaceutical company focused on the development of drug products to treat orphan and high value diseases with unmet parental delivery needs. The company’s lead drug product candidate, Trevyent®, utilizes its proprietary PatchPump drug administration platform and is currently being developed to treat pulmonary arterial hypertension. In June 2015, SteadyMed signed an exclusive license and supply agreement for the commercialization of Trevyent in a collection of viable markets – including Europe, Canada and the Middle East. For more information, visit the company’s website at www.steadymed.com.